“20.15亿美元,据我们统计是中国临床阶段小分子抗癌药金额最大的对外授权合作。” 12月22日上午,加科思(HK01167)就最新宣布的围绕泛KRAS抑制剂JAB-23E73的BD(商务拓展)召开线上沟通会。与此同时,公司股价下跌超10%,截至收盘,跌幅定格在13.58%。 无论是交易额,还是合作方阿斯利康在肿瘤药物领域的地位,都让前一晚看到这个合作消息的投资者感到期待。而且,这还是加科思...
Source Link“20.15亿美元,据我们统计是中国临床阶段小分子抗癌药金额最大的对外授权合作。” 12月22日上午,加科思(HK01167)就最新宣布的围绕泛KRAS抑制剂JAB-23E73的BD(商务拓展)召开线上沟通会。与此同时,公司股价下跌超10%,截至收盘,跌幅定格在13.58%。 无论是交易额,还是合作方阿斯利康在肿瘤药物领域的地位,都让前一晚看到这个合作消息的投资者感到期待。而且,这还是加科思...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.